Post Capital Partners

Investment decisions sit with co-founders and Managing Partners Mitch Davidson and Michael Pfeffer, who jointly lead the firm. Davidson came from Merrill Lynch's Financial Sponsors Group and Skadden's M&A practice; Pfeffer was a managing director at Charterhouse Group International and a senior vice president at GE Capital. The senior deal team includes Managing Directors Christopher Cheang and Isaac Chalal, both of whom participate in underwriting and portfolio management.

Post Capital uses an 'executive-first' model. The firm identifies and partners with a senior operating executive in a target industry before identifying an acquisition. That executive's industry relationships and corporate network often surface companies that never reach a broad auction process, functioning as a proprietary deal-sourcing channel.

Yes. Post Capital explicitly makes both majority-control and minority investments. The firm states it does not apply a 'one size fits all' approach and works with corporate, individual, and family business owners to create a customized capital solution that can include traditional buyouts, growth equity, management buyouts, or recapitalizations.

The firm targets lower middle-market companies with revenue typically between $10 million and $150 million. This range is stated on the firm's own materials and corresponds to the lower mid-market segment where institutional capital is less crowded and family or founder ownership is common.

Yes. The firm states it is currently investing from its third committed capital fund. The fund pools capital from both institutional investors and private limited partners. Exact fund size and closing date have not been publicly disclosed.

The firm lists industry-specific operating executives — such as Phil Johnson in specialty chemicals and Anthony Manley in healthcare and education services — on its own website, indicating they are embedded in the investment process. Several are former CEOs of Post Capital portfolio companies. This visibility suggests they function as deal partners or post-acquisition leaders rather than casual advisors.

Confirmed portfolio companies include Invo (healthcare and education services), DTT (security and surveillance), BHS Specialty Chemicals, Agent Media (insurance-industry data and marketing), and VerusMed (clinical news publishing). The firm's stated focus covers services, manufacturing, and distribution businesses with recurring-revenue characteristics.